-
EASL Five-Minute Briefing: Professor Jian Gao Fan Reviews Cutting-Edge Progress in MAFLD Drug Development
On June 8, the European Association for the Study of the Liver (EASL) Annual Meeting concluded successfully in Milan, Italy. This conference brought together top experts and scholars from around the world to discuss the latest technologies and future trends in liver disease treatment. Among the key topics was the development of new drugs for…
-
EHA Expert Interview with Professor Zhihui Li: Safe and Effective Use of Luspatercept Post-Allo-HSCT in Patients with Hematologic Malignancies
The 29th Annual Meeting of the European Hematology Association (EHA) was held from June 13 to 16, 2024, in Madrid, Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world to share and discuss innovative ideas and the latest scientific and clinical research…
-
EHA China’s Voice | Breakthrough Studies from Professor Huilai Zhang’s Team Unveiled at the EHA Annual Meeting – Deciphering the Genetic Secrets and New Treatment Strategies for Follicular Lymphoma
The 29th European Hematology Association (EHA) Annual Meeting took place from June 13-16, 2024, in Madrid, Spain. At this prestigious event, Professor Huilai Zhang’s team from Tianjin Medical University Cancer Institute and Hospital presented several research studies in poster sessions, highlighting the clinical features, genetic variations, and histological grading of follicular lymphoma. Their work offers…
-
Copy of Professor Jing Pan: Breakthroughs and Prospects of Performance-Enhanced CD33 CAR-T Cells in the Treatment of Relapsed or Refractory AML
In the field of hematologic oncology, treating acute myeloid leukemia (AML) has always been challenging, especially for relapsed or refractory patients. The limitations of traditional chemotherapy underscore the urgent need for innovative treatments. With advancements in immunotherapy, CAR-T cell therapy has introduced new breakthroughs in AML treatment. The 2024 American Society of Clinical Oncology (ASCO)…
-
Welcome the Asia-Pacific AIDS & Co-Infections Conference (APACC) 2024
Over the years, enormous progress has been made in the fight against HIV and co-infections. Both academia and industry have contributed greatly to equipping the medical community with the best medications and expertise possible to optimally treat people living with HIV. However, international platforms for scientific interchange are not always accessible to medical professionals worldwide…
-
EASL Interview with Professor Arun J Sanyal: Breakthroughs in MAFLD Research and Discussion on the “Sugar-Liver Co-Management” Strategy
With the changing modern lifestyle and dietary patterns, Metabolic Associated Fatty Liver Disease (MAFLD) has gradually become one of the significant public health concerns globally. At the 2024 EASL Congress, there have been groundbreaking developments in the pharmacological treatment of MAFLD. Particularly, studies on the dual receptor agonists for Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic…
-
Professor Man Li: TROP-2 ADC Combined with PD-1 Immunotherapy—SACI-IO HR+ Study Faces Challenges but Offers Valuable Insights| Man Talks Breast Cancer: ASCO Special
In this “Man Talks Breast Cancer: ASCO Special,” Professor Man Li’s team from The Second Affiliated Hospital of Dalian Medical University has selected the latest ASCO studies on HR+ advanced breast cancer, covering topics such as cross-line treatment with CDK4/6 inhibitors, novel ADCs combined with ICIs, and comparing CDK4/6 inhibitors + ET with chemotherapy in…
-
ASCO 2024丨Advances in Acute Myeloid Leukemia (AML) Treatment
Acute myeloid leukemia (AML) is a highly heterogeneous hematologic malignancy, presenting significant challenges in treatment strategies and prognosis management for clinicians. At this year’s ASCO conference, several AML studies were presented. This article highlights three of them, covering the importance of frailty assessment, exploration of shortened treatment regimens, and interim results of new therapeutic agents.…
Connecting Medical Expertise through Media